July 25, 2024 07:29 AM EDTUpdated 10:23 AM
Pharma
Manufacturing

Sanofi eyes RSV an­ti­body for its next block­buster while Dupix­ent brings in record sales

Anna Brown

News Reporter

Sanofi’s RSV an­ti­body Bey­for­tus is still on track to reach block­buster sta­tus this year as the com­pa­ny ex­pands man­u­fac­tur­ing ca­pac­i­ty, ac­cord­ing to re­marks made Thurs­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Se­cre­tive Tree­line Bio­sciences dis­clos­es $421M fi­nanc­ing in fil­ing

House’s promi­nent Chi­na crit­ic Jim Mc­Gov­ern leads op­po­si­tion to Biose­cure Act: ‘I would pre­fer to go back to the ...

Benev­o­len­tAI CEO is out af­ter less than a year on the job

FDA ap­proves Ab­b­Vie's 24-hour Parkin­son's in­fu­sion ther­a­py af­ter two CRLs

Sage shakes up se­nior man­age­ment, slash­es pipeline, sheds 33% of staff

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times